CIS Pharma AG news

CIS Pharma and the University of Applied Sciences in Basel were granted a two-year research program by the Swiss Nanoscience Institute, SNI, to develop a nanobody-radionuclide conjugate, currently at preclinical stage. The bioconjugate is based on CIS Pharma’s polymer drug carrier technology and is developed to diagnose and treat B7H3-positive forms of cancer. The target plays a role in the adaptive immune system and is overexpressed in differentiated malignant cells and cancer initiati

CIS Pharma’s new lens care patent application was published. The patent covers the latest developments in the field of contact lens care creating multi-purpose disinfecting solutions, MPDS, with an improved efficacy/safety profile. CIS Pharma’s innovation reduces the trade-off between efficacy and safety, inherent to MPDS that cover the complete contact lens care regimen with just one product.

CIS Pharma technology combines the use of three disinfectants that synergistical

CIS Pharma successfully completed the biodistribution study with its polymer carrier technology applied to an antibody radionuclide conjugate (ARC). The conjugate was tested in a SKOvip mouse model, an aggressive form of ovarian cancer. The ARC tested comprised Trastuzumab as a model antibody to which two polymer carriers were conjugated that contained several chelators for the immobilization of radionuclides like lutecium-177 or indium-111. The biodistribution including the ratio of tumor to

CIS Pharma has successful up-scaled the production of its novel contact lens multipurpose and disinfection solution (MPDS) to an industrial setup. The contact lens care solution achieved excellent performance compared to products that are leading the markets. From an efficacy perspective, the antimicrobial performance against various bacteria & fungi was tested according to ISO 14729. The primary criteria were reached within 2-4 hours, indicating the complete killing of the challeng